CTSO.O News & Events

Reports Q4 revenue $9.23M vs. $9.15M last year. "2025 was a transitional year for our business as we made good progress in four key objectives," stated Dr. Phillip Chan, CEO of CytoSorbents. "We ended the year with positive clinical and commercial momentum for 2026, with a lower cost structure and improved balance sheet to support our growth. Additionally, we continue to make progress with the FDA to align on the content and timing of a new De Novo submission for DrugSorb-ATR and look forward to providing further updates in the future."

Full-year gross margin is expected to be approximately 72%, compared to 71% for full-year 2024.

Fourth quarter gross margin is expected to be in the range of 73%-75%, compared to 71% in the fourth quarter of 2024, and 70% in the third quarter of 2025.